Edilene Oliveira da Silva
Overview
Explore the profile of Edilene Oliveira da Silva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galue-Parra A, de Moraes L, Hage A, Castro de Sena C, do Nascimento J, da Silva E
Biomed Pharmacother
. 2024 Sep;
179:117360.
PMID: 39232387
Macrophages undergo activation in response to multiple stimuli, including pathogens, growth factors and natural products. The inflammatory response and oxidative stress play critical roles in such macrophage activation. Some natural...
2.
Silva N, Lopes I, Galue-Parra A, Ferreira I, Castro de Sena C, da Silva E, et al.
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065724
A glioma is a type of tumor that acts on the Central Nervous System (CNS) in a highly aggressive manner. Gliomas can occasionally be inaccurately diagnosed and treatments have low...
3.
de Meneses Costa Ferreira L, Modesto Y, Souza P, Nascimento F, Pereira R, Converti A, et al.
Pharmaceuticals (Basel)
. 2024 May;
17(5).
PMID: 38794145
Hydrogels consist of a network of highly porous polymeric chains with the potential for use as a wound dressing. Propolis is a natural product with several biological properties including anti-inflammatory,...
4.
Queiroz-Souza P, Galue-Parra A, Silveira Moraes L, Macedo C, Rodrigues A, H S Marinho V, et al.
Front Pharmacol
. 2024 Feb;
15:1331240.
PMID: 38323082
Leishmaniasis encompasses a cluster of neglected tropical diseases triggered by kinetoplastid phatogens belonging to the genus Leishmania. Current therapeutic approaches are toxic, expensive, and require long-term treatment. Nanoparticles are emerging...
5.
de Moraes L, Galue-Parra A, Hage A, Moura H, Garcia M, Macedo C, et al.
Microorganisms
. 2023 Dec;
11(12).
PMID: 38138069
(1) Background: Leishmaniasis refers to a group of anthropozoonotic diseases caused by Leishmania. The major chemotherapeutic agent used for its treatment is Glucantime, but the search continues for new compounds...
6.
Oliveira F, Silva N, Hamoy M, Crespo-Lopez M, Ferreira I, da Silva E, et al.
Molecules
. 2022 Jun;
27(11).
PMID: 35684543
Seizures and epilepsy are some of the most common serious neurological disorders, with approximately 80% of patients living in developing/underdeveloped countries. However, about one in three patients do not respond...
7.
da Veiga A, Silveira F, da Silva E, Junior J, Araujo S, Campos M, et al.
Sci Rep
. 2022 May;
12(1):8662.
PMID: 35606396
This study evaluated the morphological changes caused by fractions and subfractions, obtained from barks of Aspidosperna nitidum, against L. (L.) amazonensis promastigotes. The ethanolic extract (EE) obtained through the maceration...
8.
Gabriel A, Galue-Parra A, Pereira W, Pedersen K, da Silva E
Microorganisms
. 2021 Oct;
9(10).
PMID: 34683402
parasites are a group of kinetoplastid pathogens that cause a variety of clinical disorders while maintaining cell communication by secreting extracellular vesicles. Emerging technologies have been adapted for the study...
9.
de Lima J, da Silva Fonseca L, Xavier L, Macchi B, Cassoli J, da Silva E, et al.
Pathogens
. 2021 Jun;
10(6).
PMID: 34071265
During tuberculosis, uses host macrophage cholesterol as a carbon and energy source. To mimic these conditions, can be cultured in minimal medium (MM) to induce cholesterol consumption in vitro. During...
10.
Agathisflavone, a Biflavonoid from Anacardium occidentale L., Inhibits Influenza Virus Neuraminidase
de Freitas C, Rocha M, Sacramento C, Marttorelli A, Ferreira A, Rocha N, et al.
Curr Top Med Chem
. 2019 Dec;
20(2):111-120.
PMID: 31854280
Background: Neuraminidase inhibitors (NAIs) are the only class of antivirals in clinical use against influenza virus approved worldwide. However, approximately 1-3% of circulating strains present resistance mutations to oseltamivir (OST),...